Navigation Links
Phase III Trial Results Show Superiority of Rivaroxaban over,Enoxaparin for the Prevention of Venous Thromboembolism in Patients,Undergoing Knee Replacement Surgery

t.

To date, rivaroxaban is the most studied oral direct Factor Xa inhibitor in development. More than 15,000 patients have been evaluated in the completed phase II programs and enrolled thus far in the phase III programs. More than 40,000 patients are expected to be evaluated in total.

The RECORD3 trial is part of the joint clinical development program led by J&JPRD and Bayer HealthCare. Upon regulatory approval, rivaroxaban will be commercialized in the United States by Scios Inc. and Ortho-McNeil, Inc. Bayer Schering Pharma will market rivaroxaban throughout the rest of the world.

The companies plan to submit regulatory filings for the prevention of VTE in orthopaedic surgery in late 2007 in Europe and in 2008 in the United States.

About Johnson & Johnson Pharmaceutical Research and Development, L.L.C. (J&JPRD)

Johnson & Johnson Pharmaceutical Research & Development, L.L.C., is part of Johnson & Johnson, the world's most broadly based producer of healthcare products. J&JPRD is headquartered in Raritan, NJ, and has facilities throughout Europe and the United States. J&JPRD is leveraging drug discovery and drug development in a variety of therapeutic areas to address unmet medical needs worldwide.

(This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the Company's expectations and projections. Risks and uncertainties include general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment

Post Your Comments:
(Date:11/6/2009)..., Nov. 6 California American Water...o Drugs Down the Drain" week for its San Diego Cou...onsored by public and private agencies alike towar...llution in our source water supplies. ,, Califo...re encouraged to drop off expired or unwanted phar...
(Date:11/5/2009)..., N.J., Nov. 5 Osteotech...field of biologic products for regenerative healin...quarter ended September 30, 2009. ,, "During th...ase of our three new biologic products MagniFuse(...d Plexur M® Innovative Grafting," said Sam Ow...
(Date:11/5/2009)...HMOND, Calif., Nov. 5 Tr...specialty pharmaceutical company focused on the de...ducts that address important therapeutic needs in ... host a webcast and teleconference with management...n Thursday, November 12, 2009, at 5:00 p.m. Easter...
Breaking Medicine Technology:California American Water Celebrates 'No Drugs Down the Drain' Week in San Diego 2Osteotech Reports Third Quarter 2009 Financial Results 2Osteotech Reports Third Quarter 2009 Financial Results 3Osteotech Reports Third Quarter 2009 Financial Results 4Osteotech Reports Third Quarter 2009 Financial Results 5Osteotech Reports Third Quarter 2009 Financial Results 6Osteotech Reports Third Quarter 2009 Financial Results 7Osteotech Reports Third Quarter 2009 Financial Results 8Transcept Pharmaceuticals to Report Third Quarter 2009 Results and Host Conference Call on November 12 2New Test Assesses Individual Breast Cancer Risk 58896 1New Test Assesses Individual Breast Cancer Risk 58896 2New Test Assesses Individual Breast Cancer Risk 58896 3Antidepressants May Be Linked to Birth Problems 58893 1Antidepressants May Be Linked to Birth Problems 58893 2VBI awarded 2427 million from NIH to support infectious disease research 10266 1VBI awarded 2427 million from NIH to support infectious disease research 10266 2VBI awarded 2427 million from NIH to support infectious disease research 10266 3VBI awarded 2427 million from NIH to support infectious disease research 10266 4
...ORK, June 13, 2007--Three new drugs for,rheumatoid...ment,for this difficult and debilitating condition...udy published early Online and in an,upcoming edit...chronic,inflammatory joint diseases, affecting 0&m...alised world. Its typical symptoms are,joint pain,...
... TIKVA, Israel--(BUSINESS WIRE)--Jun 14, 2007 - Ca...any traded on the Tel,Aviv Stock Exchange Exchange...CF502; this is in addition to CF101, which is curr...eclinical phases. This,weekend Can-Fite will prese...-vitro and in vivo study results showing effective...
Other Medicine Technology:Three New Drugs Mark New Era in Rheumatoid Arthritis Treatment 2Three New Drugs Mark New Era in Rheumatoid Arthritis Treatment 3Can-Fite Proceeds with Development of Third Drug; Progress in,Development of CF502 Will Be Presented at the Annual European,Congress of Rheumatology 2
(Date:11/8/2009)...HINGTON, Nov. 7 USActio...alth Care for America Act, which will make health ... companies accountable and increase access to heal... option. ,, "Teddy Roosevelt, FDR and Harry Tru...r Alan Charney. "Today,s vote ranks among our coun...
(Date:11/8/2009)...lls for Swift Passage of H.R. 3961 to Secure the S...swire-USNewswire/ -- Statement Attributable to: J....ssociation. ,, (Logo: http://www.newscom.com/...ails the passage of the House health reform bill, ...ents and physicians and calls for swift passage of...
(Date:11/8/2009)...RP Praises House Passage of Health Care Reform Bil...dicare, improve coverage for all Americans ,, ...the United States House of Representatives passed ...legislation that would strengthen Medicare for sen... that prices millions of Americans out of affordab...
(Date:11/8/2009)...RP Praises House Passage of Health Care Reform Bil...dicare, improve coverage for all Americans ,, ...ARY: Tonight the United States House of Represent...ion that would strengthen Medicare for seniors and...ices millions of Americans out of affordable healt...
(Date:11/7/2009)...HINGTON, Nov. 7 Karen I...rance Plans (AHIP), released the following stateme...lth plans strongly support comprehensive health ca...ion by proposing a complete overhaul of how health...osed guaranteed coverage, elimination of pre-exist...
Breaking Medicine News(10 mins):Health News:AMA Hails House Passage of Health Reform Bill (H.R. 3962) 2Health News:AARP Illinois Key Vote News Alert 2Health News:AARP Illinois Key Vote News Alert 3Health News:AARP Maryland Key Vote News Alert 2Health News:AARP Maryland Key Vote News Alert 3Health News:AHIP Statement on House Passage of H.R. 3962 2
...Explores Psychological, Social, Physical and Educa...IL (PRWEB) January 5, 2009 -- Since the advent of ...onger game play, two things have occurred in the v...nies, over what effect videos games have on childr...
...anuary 13, 2009 , 10:00 a.m. Eastern Standard Time... , Locations of Initial Recruitment , , WASHING...ional Institutes of Health: , , What: A media t...nited States, the National Children,s study will f...
...ection Saves Pets , Kansa...u commit to your new year,s resolutions or not, ve... Center of Kansas City are urging you to commit t... lead to a loved one,s life saved and less costly ...
...rging technologies can create environments that re...e University researcher thinks games like Nintendo...edentary activities for people of all ages. , "I ...department of kinesiology at K-State and director ...
...mming from the catastrophic,October 15, 2008 crash...nois,was filed today on behalf of Robert and Brook...r 14-month-old daughter Kirstin Reann Blockinger. ...al,Hospital hit a radio tower and its supporting s...
...harmaceuticals, Inc. (Nasdaq: ONXX ) today annou...hts to SB1518, an orally available, potent, and se...1578, also a JAK2 inhibitor, from S*BIO Pte Ltd ba...yx as ONX 0803) and SB1578 (designated by Onyx as ...
Other Medicine News:Health News:Psychiatrist Examines Effects of Video Game Play on Children 2Health News:Psychiatrist Examines Effects of Video Game Play on Children 3Health News:Telebriefing: National Children's Study Recruitment Begins 2Health News:Tips on When to Bring Pets to Animal ER 2Health News:Tips on When to Bring Pets to Animal ER 3Health News:Wii Fit a promising tool for all ages 2Health News:Wii Fit a promising tool for all ages 3Health News:Nolan Law Group Files Lawsuit on Behalf of the Parents of a 14-Month-Old Girl Killed in October 15th 2008 Medical Evacuation Helicopter Crash Near Aurora, Illinois 2Health News:Nolan Law Group Files Lawsuit on Behalf of the Parents of a 14-Month-Old Girl Killed in October 15th 2008 Medical Evacuation Helicopter Crash Near Aurora, Illinois 3Health News:Onyx Pharmaceuticals Acquires Option to License Novel Highly Specific JAK2 Inhibitors From S*BIO 2Health News:Onyx Pharmaceuticals Acquires Option to License Novel Highly Specific JAK2 Inhibitors From S*BIO 3Health News:Onyx Pharmaceuticals Acquires Option to License Novel Highly Specific JAK2 Inhibitors From S*BIO 4
... reference laboratory and a worldwide leader in in... offers an extensive test menu of highly complex a...athology. Owned by the University of Utah, ARUP La...nation's university teaching hospitals and childre...
... reference laboratory and a worldwide leader in in... offers an extensive test menu of highly complex a...athology. Owned by the University of Utah, ARUP La...nation's university teaching hospitals and childre...
... reference laboratory and a worldwide leader in in... offers an extensive test menu of highly complex a...athology. Owned by the University of Utah, ARUP La...nation's university teaching hospitals and childre...
... reference laboratory and a worldwide leader in in... offers an extensive test menu of highly complex a...athology. Owned by the University of Utah, ARUP La...nation's university teaching hospitals and childre...
Medicine Products: